<DOC>
	<DOCNO>NCT00032279</DOCNO>
	<brief_summary>The purpose phase II study evaluate investigational monoclonal antibody treatment glucocorticoid-refractory Graft Versus Host Disease ( GVHD ) . Patients diagnose GVHD respond satisfactorily , intolerant , treatment standard agent consider entry . Patients allow continue immunosuppressive drug stable dos trial . The research conduct 20 clinical research sit US .</brief_summary>
	<brief_title>Research Study Visilizumab Treatment Glucocorticoid- Refractory Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Grade II IV GVHD Clinical finding : skin thickening , joint contraction , oral ulceration , diarrhea . History allogeneic hematopoietic cell transplant ( HCT ) . Patients must fail respond clearly progress previous therapy day +100 posttransplant . Patients must adequate renal , hepatic , cardiac function hematologic value</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
</DOC>